Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC
Fang Yang, Yalei Wen, Chaofan Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 230, pp. 114088-114088
Closed Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 172
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 170
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 158
Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 56
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Laura Hillebrand, Xiaojun Julia Liang, Ricardo A. M. Serafim, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7668-7758
Closed Access | Times Cited: 49
Research progress on Sirtuins (SIRTs) family modulators
Mingkai Chen, Junfei Tan, Zihan Jin, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116481-116481
Open Access | Times Cited: 19
Targeting the undruggables—the power of protein degraders
Chao Zhang, Yongbo Liu, Guangchen Li, et al.
Science Bulletin (2024) Vol. 69, Iss. 11, pp. 1776-1797
Open Access | Times Cited: 19
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D
Chuan Zhou, Zisheng Fan, Yuejiao Gu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1147-1167
Closed Access | Times Cited: 17
A bibliometric analysis of PROTAC from 2001 to 2021
Deping Li, Dongmin Yu, Yan Li, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114838-114838
Closed Access | Times Cited: 66
Clinical considerations for the design of PROTACs in cancer
Cristina Nieto‐Jiménez, Esther Cabañas Morafraile, Carlos Alonso‐Moreno, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 63
Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development
Fangjiao Huang, Xiaoli Han, Xiaohui Xiao, et al.
Molecules (2022) Vol. 27, Iss. 22, pp. 7728-7728
Open Access | Times Cited: 60
PROTAC therapy as a new targeted therapy for lung cancer
Jennifer W. Li, Guangrong Zheng, Frederic J. Kaye, et al.
Molecular Therapy (2022) Vol. 31, Iss. 3, pp. 647-656
Open Access | Times Cited: 47
De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy
Bohan Ma, Yizeng Fan, Dize Zhang, et al.
Advanced Science (2022) Vol. 9, Iss. 28
Open Access | Times Cited: 41
Annual review of KRAS inhibitors in 2022
Hao Wang, Lingling Chi, Fuqiang Yu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115124-115124
Closed Access | Times Cited: 32
Design, synthesis and biological evaluation of KRASG12C-PROTACs
Xiaoyi Zhang, Tong Zhao, Minghao Sun, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 78, pp. 117153-117153
Closed Access | Times Cited: 25
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
Hydrophobic tag-based protein degradation: Development, opportunity and challenge
Qindi He, Xiaofei Zhao, Donglin Wu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115741-115741
Closed Access | Times Cited: 25
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
Tonia Kirschner, Matthias Müller, Daniel Rauh
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6044-6051
Closed Access | Times Cited: 10
Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions
Yanguo Shang, Shengnan Fu, Qingjing Hao, et al.
Bioorganic Chemistry (2024) Vol. 144, pp. 107092-107092
Closed Access | Times Cited: 9
From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
Siqi Wang, Fuchu He, Chunyan Tian, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 1, pp. 100-100
Open Access | Times Cited: 9
Advancing targeted protein degradation for metabolic diseases therapy
Qianqian Zhou, Haitao Xiao, Fan Yang, et al.
Pharmacological Research (2022) Vol. 188, pp. 106627-106627
Open Access | Times Cited: 34
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
Jianyu Yan, Tengfei Li, Zhenyuan Miao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8798-8827
Closed Access | Times Cited: 30
Applications of covalent chemistry in targeted protein degradation
Dong Lu, Xin Yu, Hanfeng Lin, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 22, pp. 9243-9261
Open Access | Times Cited: 29
Eliminating oncogenic RAS: back to the future at the drawing board
Candy Laura Steffen, Pelin Kaya, Elisabeth Schaffner‐Reckinger, et al.
Biochemical Society Transactions (2023) Vol. 51, Iss. 1, pp. 447-456
Open Access | Times Cited: 20
Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation
Ning Yang, Zhiya Fan, Shiyang Sun, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115857-115857
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top